TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

______

* Furnished herewith.

Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.01 2 s107504_ex99-01.htm EXHIBIT 99.01    Exhibit 99.01         Tonix Pharmaceuticals Receives European Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)   Patent Will Provide Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in the Treatment of Posttraumatic Stress Disorder (PTSD)   NEW YORK,…
To view the full exhibit click here